Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor recurrence after oLTX

T Gruenberger1, T Windhager, M Gnant

  • 1Department of Transplantation Surgery, University of Vienna, Austria.

Transplant International : Official Journal of the European Society for Organ Transplantation
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial.

ESMO open·2026
Same author

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

The impact of analysis methodology details on invasive breast cancer-free survival in randomized clinical trials.

ESMO open·2025
Same author

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).

ESMO open·2025
Same author

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Liver transplantation shows excellent early survival for primary hepatic cancer, but recurrence is a concern. Lower tumor grade and absence of vascular invasion significantly improve disease-free survival in these patients.

Area of Science:

  • Hepatology
  • Surgical Oncology
  • Transplantation Medicine

Background:

  • Primary hepatic cancer recurrence after liver transplantation (LTx) has historically limited its application.
  • Risk factors influencing early tumor recurrence require detailed examination to optimize patient selection and outcomes.

Purpose of the Study:

  • To retrospectively analyze risk factors associated with early tumor recurrence following liver transplantation for unresectable primary hepatic cancer.
  • To evaluate the impact of specific tumor characteristics on disease-free survival and overall patient outcomes.

Main Methods:

  • Retrospective analysis of 480 liver transplantations, focusing on 103 patients with unresectable primary hepatic cancer (88 hepatocellular cancer, 15 cholangiocellular cancer).
  • Assessment of tumor-associated risk factors including size, distribution, grading, vascular invasion, and lymph node metastasis.

Related Experiment Videos

  • Kaplan-Meier survival analysis and Cox proportional hazards model for multivariate analysis (P < 0.05 significant).

    • Main Results:

    • Tumor recurrence significantly impacted survival, with 50% of patients dying due to recurrence.
    • Hepatocellular cancer (HCCA) 1, 3, and 5-year survival rates post-orthotopic liver transplantation (oLTX) were 57%, 34%, and 26%, respectively.
    • Significantly longer disease-free periods were observed for tumors with grading ≤2 (P = 0.009) and absence of vascular invasion (P = 0.04).

    Conclusions:

    • Liver transplantation is a viable option for unresectable malignant liver tumors, offering improved survival compared to median survival rates of 2-4 months.
    • Tumor grading and vascular invasion are critical predictors of recurrence and disease-free survival after liver transplantation.
    • Careful patient selection based on tumor characteristics is crucial for successful liver transplantation outcomes in primary hepatic cancer.